Surrozen, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Surrozen, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 87% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 0 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-159.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 87% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 72%
Sales fell 72% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-72% / +10%In 3 years sales changed by -72% while total assets changed by +10%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-23.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 58% of Healthcare companies in United States.
Cash Cushion Ratio
+27%Cash, after subtracting all debt, equals 27% of its market value (net cash).
Higher than 67% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Surrozen, Inc. made a loss over the last year. Surrozen, Inc. owes $2.89 for every $1 it owns. Surrozen, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSurrozen, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-1.38Surrozen, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$303 MThe total market value of all of Surrozen, Inc.'s shares at today's price (share price × number of shares), smaller than 52% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeSurrozen, Inc.'s net worth is negative ($219 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
2.89×Surrozen, Inc. owes $2.89 for every $1 it owns, so it owes more than it owns, higher than 98% of Healthcare companies in United States.
Dividend yield
NoneSurrozen, Inc. does not currently pay a dividend.
Revenue growth
-67%Revenue fell 67% in the year to Dec 2025, and shrank 35% a year on average over 3 years.
Profit growth
LossSurrozen, Inc. made a loss in each of the last two years.
Profit margin
-6960.8%Surrozen, Inc. lost $6961 for every $100 of revenue.
Cash vs debt
Net cashSurrozen, Inc. held $83 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Surrozen, Inc. owe compared with what it owns?
Surrozen, Inc. owes $2.89 for every $1 it owns, so it owes more than it owns, higher than 98% of Healthcare companies in United States.
Does Surrozen, Inc. pay a dividend?
No. Surrozen, Inc. does not currently pay a dividend.
Is Surrozen, Inc.'s revenue growing?
Revenue fell 67% in the year to Dec 2025, and shrank 35% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.